| MeSH term | MeSH ID | Detail |
|---|---|---|
| Tenosynovitis | D013717 | 3 associated lipids |
| Splenic Diseases | D013158 | 5 associated lipids |
| Hernia, Hiatal | D006551 | 3 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
| Leprosy, Lepromatous | D015440 | 2 associated lipids |
| Gastritis, Hypertrophic | D005758 | 1 associated lipids |
| Hypoproteinemia | D007019 | 1 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Tuberculosis, Ocular | D014392 | 1 associated lipids |
| Euthyroid Sick Syndromes | D005067 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Grunden JW and Fisher KA | Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. | 1997 Jul-Aug | Ann Pharmacother | pmid:9220046 |
| Tartaglione T | Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. | 1997 Jul-Aug | Clin Ther | pmid:9377608 |
| Nawarskas JJ et al. | Digoxin toxicity secondary to clarithromycin therapy. | 1997 Jul-Aug | Ann Pharmacother | pmid:9220047 |
| al-Humayyd MS | Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. | 1997 Mar-Apr | Chemotherapy | pmid:9084915 |
| Svoboda P et al. | Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. | 1997 May-Jun | Hepatogastroenterology | pmid:9222709 |
| Best LM et al. | Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. | 1997 May-Jun | Can. J. Gastroenterol. | pmid:9218854 |
| O'Brien B et al. | Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. | 1997 May-Jun | Can. J. Gastroenterol. | pmid:9218858 |
| Guerriero SE et al. | Two cases of clarithromycin-induced digoxin toxicity. | 1997 Sep-Oct | Pharmacotherapy | pmid:9324195 |
| Anzueto A et al. | Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. | 1997 Sep-Oct | Clin Ther | pmid:9385486 |
| Soepandi P et al. | The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. | 1998 | Respirology | pmid:9692520 |
| Elliott RL et al. | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572890 |
| Griesgraber G et al. | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572891 |
| Sakaki N et al. | Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. | 1998 | J. Clin. Gastroenterol. | pmid:9872520 |
| Yoshida Y et al. | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9873455 |
| Sakurai N et al. | Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9873510 |
| Komori T et al. | Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. | 1998 | Res. Commun. Mol. Pathol. Pharmacol. | pmid:9874281 |
| Matteelli A et al. | Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report. | 1998 | J Chemother | pmid:9876056 |
| Vorbach H et al. | Endothelial cell compatibility of clarithromycin for intravenous use. | 1998 | Clin. Biochem. | pmid:9876898 |
| Miglioli PA et al. | Antibacterial activity of human pleural fluid: alone and in combination with antibiotics. | 1998 | Int. J. Antimicrob. Agents | pmid:9916908 |
| Garrido A et al. | [Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity]. | 1998 | Enferm. Infecc. Microbiol. Clin. | pmid:9918994 |
| Matsushima T and Miyashita N | [Basic and clinical study of Chlamydia pneumoniae infections]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9922675 |
| Stefansson P et al. | Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. | 1998 | Rhinology | pmid:9923060 |
| Nelson KG et al. | Results of operation in Mycobacterium avium-intracellulare lung disease. | 1998 | Ann. Thorac. Surg. | pmid:9725364 |
| Sung JJ et al. | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726384 |
| Pazzi P et al. | Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726385 |
| Harris AW et al. | Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726387 |
| Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
| Bermudez LE et al. | Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. | 1998 | J. Infect. Dis. | pmid:9728568 |
| Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
| Gorski JC et al. | The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. | 1998 | Clin. Pharmacol. Ther. | pmid:9728893 |
| Cammarota G et al. | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678813 |
| Barzilai A et al. | Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. | 1998 | Scand. J. Infect. Dis. | pmid:9730300 |
| Louw JA et al. | Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678814 |
| Graham DY et al. | Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. | 1998 | Helicobacter | pmid:9731987 |
| Ahuja V et al. | Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678815 |
| Bazzoli F et al. | Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. | 1998 | Helicobacter | pmid:9731991 |
| Grübel P and Cave DR | Factors affecting solubility and penetration of clarithromycin through gastric mucus. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678818 |
| Lanza FL et al. | Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. | 1998 | Helicobacter | pmid:9731994 |
| Vakil N et al. | Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. | 1998 | Am. J. Gastroenterol. | pmid:9732920 |
| Chu KM et al. | A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. | 1998 | Am. J. Gastroenterol. | pmid:9732921 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Ouellet D et al. | Pharmacokinetic interaction between ritonavir and clarithromycin. | 1998 | Clin. Pharmacol. Ther. | pmid:9797791 |
| Chodosh S et al. | Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. | 1998 | Clin. Infect. Dis. | pmid:9798025 |
| Craft JC et al. | Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS. | 1998 | Clin. Infect. Dis. | pmid:9798037 |
| Shafran SD | Clarithromycin prophylaxis for disseminated Mycobacterium avium complex infection--efficacy and acquired resistance. | 1998 | Clin. Infect. Dis. | pmid:9798038 |
| Cestari R | Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798804 |
| Sakamoto M et al. | [Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer]. | 1998 | Gan To Kagaku Ryoho | pmid:9881083 |
| Komori T et al. | Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. | 1998 | Biol. Pharm. Bull. | pmid:9881659 |
| Shafran SD et al. | Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. | 1998 | J. Infect. Dis. | pmid:9419201 |
| MartÃn Mir ML et al. | [Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule]. | 1998 | Gastroenterol Hepatol | pmid:9882932 |
| van Aarem A et al. | Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. | 1998 | Int. J. Pediatr. Otorhinolaryngol. | pmid:9596371 |
| Gisbert JP et al. | [Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?]. | 1998 | Med Clin (Barc) | pmid:9887438 |
| Koster F | Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. | 1998 | Clin. Infect. Dis. | pmid:9597260 |
| Baena DÃez JM et al. | [Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care]. | 1998 | Aten Primaria | pmid:9887574 |
| Blum AL et al. | Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. | 1998 | N. Engl. J. Med. | pmid:9862942 |
| Maeda S et al. | Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. | 1998 | Gut | pmid:9863474 |
| Dhawan VK et al. | Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients. | 1998 | West. J. Med. | pmid:9830355 |
| Carlson LD et al. | Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. | 1998 | J. Clin. Microbiol. | pmid:9508306 |
| Sato K et al. | Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. | 1998 | J. Antimicrob. Chemother. | pmid:9511040 |
| Alegre Herrera S et al. | [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. | 1998 | An Med Interna | pmid:9522506 |
| Berquist WE | New, improved Helicobacter pylori eradication therapy in children. | 1998 | J. Pediatr. Gastroenterol. Nutr. | pmid:9523877 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Gisbert JP et al. | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. | 1998 | Med Clin (Barc) | pmid:9527978 |
| Kusuhara H et al. | Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. | 1998 | J. Gastroenterol. | pmid:9497215 |
| Dubois A et al. | Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. | 1998 | J. Gastroenterol. | pmid:9497216 |
| Arimori K et al. | Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin. | 1998 | Biopharm Drug Dispos | pmid:9818709 |
| Sanfélix Genovés J et al. | [Helicobacter pylori: 6-day triple therapy in duodenal ulcer]. | 1998 | Aten Primaria | pmid:9670578 |
| Cirioni O et al. | In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. | 1998 | J. Antimicrob. Chemother. | pmid:9818742 |
| de Boer WA et al. | Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. | 1998 | Am. J. Gastroenterol. | pmid:9672338 |
| Vrioni G et al. | Treatment of disseminated Mycobacterium genavense infection in a murine model with ciprofloxacin, amikacin, ethambutol, clarithromycin and rifabutin. | 1998 | J. Antimicrob. Chemother. | pmid:9818747 |
| Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
| Martin SJ and Pendland SL | Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. | 1998 | J. Antimicrob. Chemother. | pmid:9687103 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Bigard MA et al. | One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9690730 |
| Bardhan KD et al. | Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692693 |
| Catalano F et al. | Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692702 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| Dobrilla G et al. | Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692703 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| Harris A | Current regimens for treatment of Helicobacter pylori infection. | 1998 | Br. Med. Bull. | pmid:9604443 |
| Doherty TM and Sher A | IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. | 1998 | J. Immunol. | pmid:9605144 |
| Moayyedi P et al. | Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. | 1998 | J. Gastroenterol. | pmid:9605943 |
| Klein JO | Clarithromycin and azithromycin. | 1998 | Pediatr. Infect. Dis. J. | pmid:9655546 |
| Howden CW and Hunt RH | Treating Helicobacter pylori. | 1998 | Arch. Intern. Med. | pmid:9827792 |
| Apseloff G et al. | Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. | 1998 | J Clin Pharmacol | pmid:9753212 |
| Calvet Calvo X | [Treatment of Helicobacter pylori infections]. | 1998 | Gastroenterol Hepatol | pmid:9633184 |
| Bayoumi AM and Redelmeier DA | Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. | 1998 | AIDS | pmid:9727572 |
| Wang G et al. | Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates. | 1998 | J. Clin. Microbiol. | pmid:9705423 |
| van der Wouden EJ et al. | One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. | 1998 | Am. J. Gastroenterol. | pmid:9707042 |
| Burman WJ et al. | Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. | 1998 | AIDS | pmid:9708410 |
| Bergmann JS and Woods GL | In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. | 1998 | Int. J. Tuberc. Lung Dis. | pmid:9712275 |
| Alder JD et al. | Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. | 1998 | Antimicrob. Agents Chemother. | pmid:9736568 |
| Améndola R et al. | [Is dental plaque a normal Helicobacter pylori reservoir?]. | 1998 | Acta Gastroenterol. Latinoam. | pmid:9713656 |
| Takizawa H et al. | Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. | 1998 | Eur. Respir. J. | pmid:9701415 |
| Wharton JR et al. | Erythrasma treated with single-dose clarithromycin. | 1998 | Arch Dermatol | pmid:9645634 |
| Shimoyama T et al. | [Antibiotic therapy in eradicating Helicobacter pylori infections]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648426 |
| Kimura K and Sato K | [Recent topics on Helicobacter pylori--Historic background and problems caused by bacteria]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648427 |
| Aoyama N | [Efficacy of antibiotic therapy in eradicating Helicobacter pylori]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648439 |
| Sato R et al. | [Problems following antibiotic therapy for eradication of Helicobacter pylori]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648440 |
| Greenblatt DJ et al. | Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. | 1998 | Clin. Pharmacol. Ther. | pmid:9757151 |